Put It on the Board
March 2026—The College of American Pathologists (CAP) emphasizes the complementary role of AI in pathology, highlighting the need for local pathologists to evaluate AI system performance.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
All Issues
Letters
March 2026—Pathologists’ assistants (PAs) are vital to pathology practice, but there is room for improvement in collaboration with pathologists.
How rapid sequencing in the NICU plays out
February 2026—Rapid genome sequencing in neonatal intensive care units is a complex process involving a multidisciplinary team, including pathologists, genetic counselors, and clinicians. The goal is to identify genetic causes of complex medical conditions in newborns, often born prematurely with multiple health issues.
At USCAP, a close look at GI biomarkers
February 2026—At the USCAP 2026 meeting, two guidelines on gastrointestinal pathology biomarkers will be presented. The updated guideline on HER2 testing in gastroesophageal adenocarcinoma reaffirms IHC with follow-up ISH as the best method for …
Digital path practices reflected in latest checklist changes
February 2026—The 2025 accreditation checklist edition, released December 9, includes revisions to address the use of digital pathology platforms in laboratories.
Close-up on traditional lab biomarkers for MS
February 2026—The 2024 revision of the 2017 McDonald criteria for diagnosing multiple sclerosis allows the kappa-free light chain index to replace oligoclonal band detection in cerebrospinal fluid analysis.
Lab reins in magnesium tests with decision support
February 2026—Washington University in St. Louis implemented a clinical decision support intervention to reduce unnecessary magnesium testing.
NTRK1-rearranged spindle cell sarcoma in an unusual location: molecular confirmation resolving a high-grade pediatric sarcoma differential
February 2026—A six-year-old boy presented with abdominal pain and was found to have a large mediastinal mass. Biopsy revealed a spindle cell sarcoma, and molecular testing identified an NTRK1 rearrangement, confirming the diagnosis of NTRK1-rearranged spindle cell sarcoma.
Pathologists, vendors talk LIS-IMS integration
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
From the President’s Desk
February 2026—The pathology community must embrace new technologies, such as digital pathology and AI, to avoid being left behind.